CROISSY-BEAUBOURG, France & MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, announced today its consolidated revenues for the first quarter of 2016.
|In €K||Q1 2016||Q1 2015||Change|
|of which LISA TRACKER® revenues||903||272||x3.3|
|of which IVD revenues||1,282||1,184||+8%|
In the first quarter of 2016, Theradiag generated consolidated revenue of €2.2 million, up 50% year-over-year. Growth was driven in particular by the theranostics business unit and strong revenue growth in LISA TRACKER kits (up by a factor of 3.3 compared with the first quarter of 2015), including sales of kits to its partners UCB and Hospira. The sharp increase in revenues was also partly due to very strong export sales growth.
Sales of IVD products grew 8%, with molecular biology tests rising 26%.
International sales also increased, with revenue of €1.1 million in Q1 2016.
Michel Finance, Chief Executive Officer of Theradiag, made the following comments: "This first-quarter performance reflects the strong momentum and development in our theranostics business, along with the build-up in our partnerships with UCB and Hospira, which we signed in 2015. Our rapid Q1 revenue growth means that we expect growth to be solid for 2016 as a whole, and much faster than in the previous two years. We are aiming for 15-20% revenue growth in 2016 compared with 2015. From 2017, growth will also be driven strongly by the launch of Auto-Immunity and Tracker ranges on the BioCLIA 1200 instrument, which was recently unveiled in the International Congress on Autoimmunity (ICA) in Leipzig. In the ICA congress, we presented this new instrument and its performance to 2,000 key opinion leaders in autoimmune diseases1."
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
1 See press release of April 6, 2016: Launch of a new fully automated diagnostics system